• Politics
  • Diversity, equity and inclusion
  • Financial Decision Making
  • Telehealth
  • Patient Experience
  • Leadership
  • Point of Care Tools
  • Product Solutions
  • Management
  • Technology
  • Healthcare Transformation
  • Data + Technology
  • Safer Hospitals
  • Business
  • Providers in Practice
  • Mergers and Acquisitions
  • AI & Data Analytics
  • Cybersecurity
  • Interoperability & EHRs
  • Medical Devices
  • Pop Health Tech
  • Precision Medicine
  • Virtual Care
  • Health equity

Viz.ai Raises $50M to Expand AI-Powered Stroke ID Platform


The tech could lead to cost savings and improved patient outcomes.


Photo/Thumb have been modified. Courtesy of medistock - stock.adobe.com.

Viz.ai today announced a $50 million Series B funding round to expand the benefits of its artificial intelligence (AI)-powered platform which improves stroke care.

Its acute ischemic stroke software uses deep-learning algorithms to identify a suspected large occlusion stroke in a CT scan and automatically notify specialists. Alerting the care provider at the right time and synchronizing care leads to quicker time to treatment and the potential for better patient outcomes.

“Viz.ai’s mission is to improve access to lifesaving treatments,” said Chris Mansi, M.D., MBA. “In stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient.”

The company plans to use the funding to expand the benefits of synchronized care to other disease states and geographies.

The software is currently in use in more than 300 hospitals across the U.S.

“Viz.ai shortens time to treatment, increases the number of patients able to receive lifesaving therapy and allows us to provide the best care for our patients,” said J Mocco, M.D., professor and vice chair of the neurosurgery department at Mount Sinai Health System. “With stroke being the number one cause of long-term disability, every minute counts.”

Greenoaks led the funding, with additional participation from Threshold Ventures, CRV and existing investors GV and Kleiner Perkins.

The funding comes three months after Viz.ai and Medtronic announced a partnership for the medical technology company to distribute the large vessel occlusion detection and triage software.

The clinical decision software is cleared by the U.S. Food and Drug Administration (FDA), but it is not the only technology of this kind.

RAPID by iSchemaView is also cleared by the FDA and uses AI to aid clinicians in diagnosing and treating stroke victims more quickly.

Get the best insights in digital health directly to your inbox.


Machine Learning Automates Analysis of CTA for Stroke Patients

IBM Develops Virtual Assistant to Aid Stroke Patients

Kaiser Permanente Is Using Telemedicine to Speed Up Stroke Treatment

Related Videos
Image: Ron Southwick, Chief Healthcare Executive
George Van Antwerp, MBA
Edmondo Robinson, MD
Craig Newman
Related Content
© 2024 MJH Life Sciences

All rights reserved.